The European Alliance for Responsible R&D and Affordable Medicines sprang out of a price conflict between Germany, France and the US drug producer Gilead on price of Sovaldi, a treatment for hepatitis C, in 2014. Rich Western countries such as France and Italy couldn’t afford the drug for all their patients. That was the first [...]
;